BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 29, 2009
View Archived Issues
Exelixis Shares Soar on $1B Cancer Drug Deal with Sanofi
If all goes according to plan, Exelixis Inc. could bank more than $1 billion under a new licensing and discovery deal with Sanofi-Aventis Group for phosphoinositide-3 kinase (PI3K) inhibitors targeting cancer. (BioWorld Today)
Read More
Phase II Trial Update Triggers Wild Ride for Peregrine Shares
Read More
'Finished' Mouse Genome Is Still a Work in Progress
Read More
As Markets Brighten, Medivation Seeks $65.8M in Shares Offering
Read More
Neuropharm Revives Autism Drug, Rises on Partner Talks
Read More
Amylin 'Back to Business' Following Contentious Vote
Read More
Other News To Note
Read More
Clinic Roundup
Read More